488 related articles for article (PubMed ID: 14983219)
21. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
Foekens JA; Ries C; Look MP; Gippner-Steppert C; Klijn JG; Jochum M
Cancer Res; 2003 Jan; 63(2):337-41. PubMed ID: 12543785
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; van Putten WL; Benraad TJ; Foekens JA
Br J Cancer; 1999 Mar; 79(7-8):1190-8. PubMed ID: 10098758
[TBL] [Abstract][Full Text] [Related]
23. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
24. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
25. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Descotes F; Riche B; Saez S; De Laroche G; Datchary J; Roy P; André J; Bobin JY
Clin Breast Cancer; 2008 Apr; 8(2):168-77. PubMed ID: 18621614
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566
[TBL] [Abstract][Full Text] [Related]
29. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
30. The prognostic value of BCAR1 in patients with primary breast cancer.
Dorssers LC; Grebenchtchikov N; Brinkman A; Look MP; van Broekhoven SP; de Jong D; Peters HA; Portengen H; Meijer-van Gelder ME; Klijn JG; van Tienoven DT; Geurts-Moespot A; Span PN; Foekens JA; Sweep FC
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6194-202. PubMed ID: 15448007
[TBL] [Abstract][Full Text] [Related]
31. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
32. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Kobayashi H; Fujishiro S; Terao T
Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854
[TBL] [Abstract][Full Text] [Related]
33. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
34. A new look at node-negative breast cancer.
Harbeck N; Thomssen C
Oncologist; 2010; 15 Suppl 5():29-38. PubMed ID: 21138953
[TBL] [Abstract][Full Text] [Related]
35. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
Pappot H; Pedersen AN; Brünner N; Christensen IJ
Lung Cancer; 2006 Feb; 51(2):193-200. PubMed ID: 16325301
[TBL] [Abstract][Full Text] [Related]
36. Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
Ruppert C; Ehrenforth S; Scharrer I; Halberstadt E
Cancer Detect Prev; 1997; 21(5):452-9. PubMed ID: 9307848
[TBL] [Abstract][Full Text] [Related]
37. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
38. High levels of uPA and PAI-1 predict a good response to anthracyclines.
Borstnar S; Sadikov A; Mozina B; Cufer T
Breast Cancer Res Treat; 2010 Jun; 121(3):615-24. PubMed ID: 20039121
[TBL] [Abstract][Full Text] [Related]
39. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
[TBL] [Abstract][Full Text] [Related]
40. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
Foekens JA; Buessecker F; Peters HA; Krainick U; van Putten WL; Look MP; Klijn JG; Kramer MD
Cancer Res; 1995 Apr; 55(7):1423-7. PubMed ID: 7882345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
